1. Overcoming Therapeutic Inertia with Inhaled Insulin Therapy. Diabetes Technol Ther. 2026 Feb; 28(1_suppl):70S-76S. Blevins TC, Edelman SV. PMID: 41622411.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  2. Dosing Afrezza: It's Not that Complicated. Diabetes Technol Ther. 2026 Feb; 28(1_suppl):8S-13S. Edelman SV, Blevins TC, Parkin CG, Hirsch IB. PMID: 41622417.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  3. HEDIS glycemic goal achieved using control-IQ Technology. Am J Manag Care. 2025 Dec 01; 31(12):e357-e363. Patel BV, Wang SM, Messer LH, Pinsker JE, Polin MR, Hirsch IB, Ekhlaspour L, Edelman S, Brixner DI, Stemple C. PMID: 41512265.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  4. Risk of new-onset type 1 diabetes in individuals with celiac disease and thyroid disease-An observational study. Diabetes Obes Metab. 2025 Aug; 27(8):4229-4238. Edelman SV, Agardh D, Cui N, Hao L, Wieloch M, Meneghini L. PMID: 40437819; PMCID: PMC12232353.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  5. Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Health Care Costs: A Comparative Analysis by Insurance Type. Clin Diabetes. 2025; 43(3):399-408. Allaire JC, Dennis C, Wright EE, Edelman SV, Masturzo A. PMID: 40741455; PMCID: PMC12304568.

    View in:

    PubMed   Mentions:
  6. Improved glycemic outcomes in people with type 2 diabetes using smart blood glucose monitoring integrated with popular digital health therapeutics. Sci Rep. 2025 Mar 14; 15(1):8871. Grady M, Holt E, Cameron H, Edelman S. PMID: 40087464; PMCID: PMC11909182.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans
  7. Expert Clinical Interpretation of Continuous Glucose Monitor Reports From Individuals Without Diabetes. J Diabetes Sci Technol. 2025 Feb 12; 19322968251315171. Spartano NL, Prescott B, Walker ME, Shi E, Venkatesan G, Fei D, Lin H, Murabito JM, Ahn D, Battelino T, Edelman SV, Fleming GA, Freckmann G, Galindo RJ, Joubert M, Lansang MC, Mader JK, Mankovsky B, Mathioudakis NN, Mohan V, Peters AL, Shah VN, Spanakis EK, Waki K, Wright EE, Zilbermint M, Wolpert HA, Steenkamp DW. PMID: 39936548; PMCID: PMC11822776.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       
  8. Inadequate insurance coverage for overweight/obesity management. Am J Manag Care. 2024 Aug; 30(8):365-371. Miller E, Edelman S, Campos C, Anderson JE, Parkin CG, Polonsky WH. PMID: 39146485.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  9. Addressing the Burden of Multiple Daily Insulin Injections in Type 2 Diabetes with Insulin Pump Technology: A Narrative Review. Diabetes Ther. 2024 Jul; 15(7):1525-1534. Brixner D, Edelman SV, Sieradzan R, Gavin JR. PMID: 38771470; PMCID: PMC11211306.

    View in:

    PubMed

       Mentions:

    2  
  10. Prioritizing Patient Experiences in the Management of Diabetes and Its Complications: An Endocrine Society Position Statement. J Clin Endocrinol Metab. 2024 Apr 19; 109(5):1155-1178. Kalyani RR, Allende-Vigo MZ, Antinori-Lent KJ, Close KL, Das SR, Deroze P, Edelman SV, El Sayed NA, Kerr D, Neumiller JJ, Norton A. PMID: 38381587.

    View in:

    PubMed

       Mentions:

    6  

       Fields: 

       Translation:

    Humans
  11. Patient Perspectives on the Benefits and Challenges of Diabetes and Digital Technology. Clin Diabetes. 2024; 42(2):243-256. Edelman S, Cheatham WW, Norton A, Close KL. PMID: 38666210; PMCID: PMC11040029.

    View in:

    PubMed

       Mentions:

    4  
  12. Early Intervention by Family Physicians to Delay Type 1 Diabetes. J Fam Pract. 2023 07; 72(6 Suppl):S19-S24. Edelman S. PMID: 37549417.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans
  13. Identifying patients with type 2 diabetes who might benefit from insulin pump therapy: Literature review, clinical opportunities, potential benefits and challenges. Diabetes Obes Metab. 2023 07; 25 Suppl 2:3-20. Ekanayake P, Edelman S. PMID: 36949618.

    View in:

    PubMed

       Mentions:

    4  

       Fields: 

       Translation:

    Humans
  14. Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100). Clin Diabetes. 2023; 41(3):425-434. Edelman S, Goldman J, Malone DC, Preblick R, Munaga K, Li X, Gill J, Gangi S. PMID: 37456096; PMCID: PMC10338281.

    View in:

    PubMed

       Mentions:

    2  
  15. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol. 2023 03 16; 22(1):59. Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, Davies M, Edelman S, Forst T, Giorgino F, Green J, Groop PH, Hadjadj S, J L Heerspink H, Hompesch M, Izthak B, Ji L, Kanumilli N, Mankovsky B, Mathieu C, Miszon M, Mustafa R, Nauck M, Pecoits-Filho R, Pettus J, Ranta K, Rodbard HW, Rossing P, Ryden L, Schumm-Draeger PM, Solomon SD, Škrha J, Topsever P, Vilsbøll T, Wilding J, Standl E. PMID: 36927451; PMCID: PMC10019427.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans
  16. Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin. Clin Diabetes. 2023; 41(2):244-257. Goldman JD, Angueira-Serrano E, Gonzalez JS, Pang C, Tait J, Edelman S. PMID: 37092159; PMCID: PMC10115766.

    View in:

    PubMed   Mentions:
  17. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial. Diabetes Obes Metab. 2023 02; 25(2):545-555. Battelino T, Danne T, Edelman SV, Choudhary P, Renard E, Westerbacka J, Mukherjee B, Pilorget V, Coudert M, Bergenstal RM. PMID: 36263928; PMCID: PMC10100006.

    View in:

    PubMed

       Mentions:

    17  

       Fields: 

       Translation:

    Humans
  18. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist. J Manag Care Spec Pharm. 2022 Sep; 28(9):958-968. Edelman S, Cassarino D, Kayne D, Dex T, Li X, Pasquel FJ. PMID: 36001104; PMCID: PMC10373043.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans
  19. New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 Diabetes. Endocr Pract. 2022 Aug; 28(8):811-821. Kerr D, Edelman S, Vespasiani G, Khunti K. PMID: 35452813.

    View in:

    PubMed

       Mentions:

    14  

       Fields: 

       Translation:

    Humans
  20. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. J Diabetes Sci Technol. 2023 09; 17(5):1226-1242. Klonoff DC, Wang J, Rodbard D, Kohn MA, Li C, Liepmann D, Kerr D, Ahn D, Peters AL, Umpierrez GE, Seley JJ, Xu NY, Nguyen KT, Simonson G, Agus MSD, Al-Sofiani ME, Armaiz-Pena G, Bailey TS, Basu A, Battelino T, Bekele SY, Benhamou PY, Bequette BW, Blevins T, Breton MD, Castle JR, Chase JG, Chen KY, Choudhary P, Clements MA, Close KL, Cook CB, Danne T, Doyle FJ, Drincic A, Dungan KM, Edelman SV, Ejskjaer N, Espinoza JC, Fleming GA, Forlenza GP, Freckmann G, Galindo RJ, Gomez AM, Gutow HA, Heinemann L, Hirsch IB, Hoang TD, Hovorka R, Jendle JH, Ji L, Joshi SR, Joubert M, Koliwad SK, Lal RA, Lansang MC, Lee WA, Leelarathna L, Leiter LA, Lind M, Litchman ML, Mader JK, Mahoney KM, Mankovsky B, Masharani U, Mathioudakis NN, Mayorov A, Messler J, Miller JD, Mohan V, Nichols JH, Nørgaard K, O'Neal DN, Pasquel FJ, Philis-Tsimikas A, Pieber T, Phillip M, Polonsky WH, Pop-Busui R, Rayman G, Rhee EJ, Russell SJ, Shah VN, Sherr JL, Sode K, Spanakis EK, Wake DJ, Waki K, Wallia A, Weinberg ME, Wolpert H, Wright EE, Zilbermint M, Kovatchev B. PMID: 35348391; PMCID: PMC10563532.

    View in:

    PubMed

       Mentions:

    105  

       Fields: 

       Translation:

    Humans
  21. Practical Strategies to Help Reduce Added Sugars Consumption to Support Glycemic and Weight Management Goals. Clin Diabetes. 2021 Jan; 39(1):45-56. Warshaw H, Edelman SV. PMID: 33551553; PMCID: PMC7839604.

    View in:

    PubMed

       Mentions:

    11  
  22. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2. Diabetes Obes Metab. 2021 03; 23(3):854-860. Danne T, Edelman S, Frias JP, Ampudia-Blasco FJ, Banks P, Jiang W, Davies MJ, Sawhney S. PMID: 33289297.

    View in:

    PubMed

       Mentions:

    9  

       Fields: 

       Translation:

    Humans
  23. Utilizing continuous glucose monitoring in primary care practice: What the numbers mean. Prim Care Diabetes. 2021 04; 15(2):199-207. Edelman SV, Cavaiola TS, Boeder S, Pettus J. PMID: 33257275.

    View in:

    PubMed

       Mentions:

    14  

       Fields: 

       Translation:

    Humans
  24. Demographic characteristics and acute complications among adults with type 1 diabetes: Comparison of two multicentre databases from Germany and the United States. J Diabetes Complications. 2021 03; 35(3):107812. Eckert AJ, Zhou FL, Grimsmann JM, Pettus JH, Kerner W, Miller KM, Stechemesser L, Edelman SV, Spies C, Holl RW, Ibald-Mulli AM. PMID: 33280985.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  25. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol. 2020 10; 8(10):845-854. Groop PH, Dandona P, Phillip M, Gillard P, Edelman S, Jendle J, Xu J, Scheerer MF, Thoren F, Iqbal N, Repetto E, Mathieu C. PMID: 32946821.

    View in:

    PubMed

       Mentions:

    32  

       Fields: 

       Translation:

    HumansCTClinical Trials
  26. Comparison of Second-Generation Basal Insulin Analogs: A Review of the Evidence from Continuous Glucose Monitoring. Diabetes Technol Ther. 2021 01; 23(1):20-30. Battelino T, Edelman SV, Nishimura R, Bergenstal RM. PMID: 32700970.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans
  27. Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the US. Pharmacoecon Open. 2020 Sep; 4(3):519-528. Edelman S, Zhou FL, Preblick R, Verma S, Paranjape S, Davies MJ, Joish VN. PMID: 31997126; PMCID: PMC7426334.

    View in:

    PubMed

       Mentions:

    3  
  28. Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design. Diabetes Ther. 2020 Aug; 11(8):1907-1908. Battelino T, Bosnyak Z, Danne T, Mukherjee B, Edelman S, Pilorget V, Choudhary P, Renard E, Bergenstal R. PMID: 32578133; PMCID: PMC7376792.

    View in:

    PubMed

       Mentions:

    1  
  29. Patients With Type 2 Diabetes Are Willing to Do More to Overcome Therapeutic Inertia: Results From a Double-Blind Survey. Clin Diabetes. 2020 Jul; 38(3):222-229. Edelman SV, Wood R, Roberts M, Shubrook JH. PMID: 32699470; PMCID: PMC7364461.

    View in:

    PubMed

       Mentions:

    1  
  30. Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design. Diabetes Ther. 2020 Jul; 11(7):1607-1608. Battelino T, Bosnyak Z, Danne T, Mukherjee B, Edelman S, Pilorget V, Choudhary P, Renard E, Bergenstal R. PMID: 32361833; PMCID: PMC7324444.

    View in:

    PubMed

       Mentions:

    1  
  31. InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design. Diabetes Ther. 2020 Apr; 11(4):1017-1027. Battelino T, Bosnyak Z, Danne T, Mukherjee B, Edelman S, Pilorget V, Choudhary P, Renard E, Bergenstal R. PMID: 32100192; PMCID: PMC7136362.

    View in:

    PubMed

       Mentions:

    10  
  32. A Tribute to Robert Roy Henry-The Classic "Academic Triple Threat": Accomplished Researcher, Inspiring Teacher, and Compassionate Clinician. Diabetes Care. 2020 03; 43(3):522-525. Edelman S, Olefsky J, Mudaliar S, Ciaraldi T, Baron A. PMID: 31964787.

    View in:

    PubMed   Mentions:

       Fields: 

       
  33. Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real-world study of more than 30 000 patients in a US electronic health record database. Diabetes Obes Metab. 2020 04; 22(4):622-630. Pettus JH, Zhou FL, Shepherd L, Mercaldi K, Preblick R, Hunt PR, Paranjape S, Miller KM, Edelman SV. PMID: 31789439; PMCID: PMC7079022.

    View in:

    PubMed

       Mentions:

    9  

       Fields: 

       Translation:

    Humans
  34. Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients. Clin Diabetes. 2019 Oct; 37(4):386-390. Blumer I, Novak LM, Edelman S, Cavaiola TS. PMID: 31660014; PMCID: PMC6794219.

    View in:

    PubMed

       Mentions:

    1  
  35. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study. J Manag Care Spec Pharm. 2019 Dec; 25(12):1420-1431. Edelman SV, Ermakova A, Xiong Y, Sieradzan R, Taylor SD. PMID: 31550190; PMCID: PMC10398325.

    View in:

    PubMed

       Mentions:

    4  

       Fields: 

       Translation:

    Humans
  36. Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study. Diabetes Care. 2019 12; 42(12):2220-2227. Pettus JH, Zhou FL, Shepherd L, Preblick R, Hunt PR, Paranjape S, Miller KM, Edelman SV. PMID: 31548241.

    View in:

    PubMed

       Mentions:

    76  

       Fields: 

       Translation:

    Humans
  37. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring. Diabetes Obes Metab. 2019 08; 21(8):1906-1913. Pettus J, Gill J, Paranjape S, Stewart J, Malla S, Edelman S, Bergenstal RM, Bode B. PMID: 30993855.

    View in:

    PubMed

       Mentions:

    5  

       Fields: 

       Translation:

    HumansCTClinical Trials
  38. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials. Diabetes Obes Metab. 2019 04; 21 Suppl 2:62-77. Boeder S, Edelman SV. PMID: 31081593; PMCID: PMC6899736.

    View in:

    PubMed

       Mentions:

    23  

       Fields: 

       Translation:

    Humans
  39. Physician-patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes - New findings from the global IntroDia® study. Diabetes Res Clin Pract. 2019 Mar; 149:89-97. Edelman S, Belton A, Down S, Alzaid A, Capehorn M, Gamerman V, Nagel F, Lee J, Emmerson J, Polonsky WH. PMID: 30685350.

    View in:

    PubMed

       Mentions:

    4  

       Fields: 

       Translation:

    Humans
  40. A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 Diabetes. J Diabetes Sci Technol. 2019 09; 13(5):881-889. Davies M, Bain S, Charpentier G, Flacke F, Goyeau H, Woloschak M, Hasslacher C, Vespasiani G, Edelman S. PMID: 30646755; PMCID: PMC6955447.

    View in:

    PubMed

       Mentions:

    15  

       Fields: 

       Translation:

    HumansCTClinical Trials
  41. Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® study. Diabetes Res Clin Pract. 2019 Feb; 148:179-188. Down S, Alzaid A, Polonsky WH, Belton A, Edelman S, Gamerman V, Nagel F, Lee J, Emmerson J, Capehorn M. PMID: 30641173.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       Translation:

    Humans
  42. Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical Practice. Diabetes Educ. 2019 02; 45(1_suppl):3S-20S. Kruger DF, Edelman SV, Hinnen DA, Parkin CG. PMID: 30541402.

    View in:

    PubMed

       Mentions:

    21  

       Fields: 

       Translation:

    Humans
  43. Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. Diabetes Care. 2018 11; 41(11):2265-2274. Edelman SV, Argento NB, Pettus J, Hirsch IB. PMID: 30348844.

    View in:

    PubMed

       Mentions:

    84  

       Fields: 

       Translation:

    Humans
  44. Recommendations for Initiating Use of Afrezza Inhaled Insulin in Individuals with Type 1 Diabetes. Diabetes Technol Ther. 2018 06; 20(6):448-451. Pettus J, Santos Cavaiola T, Edelman SV. PMID: 29901406.

    View in:

    PubMed

       Mentions:

    8  

       Fields: 

       Translation:

    Humans
  45. A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN. Endocr Pract. 2018 Feb; 24(2):195-204. Dolinar R, Lavernia F, Edelman S. PMID: 29466056.

    View in:

    PubMed

       Mentions:

    5  

       Fields: 

       Translation:

    Humans
  46. Response to Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care 2017;40:1425-1432. Diabetes Care. 2018 02; 41(2):e18. Edelman SV, Polonsky WH. PMID: 29358472.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  47. Taking Control Of Your Diabetes: An Innovative Approach to Improving Diabetes Care Through Educating, Motivating, and Making the Connection Between Patients and Health Care Providers. Clin Diabetes. 2017 Dec; 35(5):333-339. Edelman SV. PMID: 29263578; PMCID: PMC5734181.

    View in:

    PubMed

       Mentions:

    2  
  48. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists. J Fam Pract. 2017 Oct; 66(10 Suppl):S12-S16. Edelman SV. PMID: 28991932.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  49. Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey. Diabetes Obes Metab. 2018 02; 20(2):301-308. Berard L, Bonnemaire M, Mical M, Edelman S. PMID: 28719066; PMCID: PMC5811840.

    View in:

    PubMed

       Mentions:

    44  

       Fields: 

       Translation:

    Humans
  50. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care. 2017 11; 40(11):1425-1432. Edelman SV, Polonsky WH. PMID: 28801473.

    View in:

    PubMed

       Mentions:

    132  

       Fields: 

       Translation:

    Humans
  51. Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes. Diabetes Care. 2017 11; 40(11):1469-1478. Carls GS, Tuttle E, Tan RD, Huynh J, Yee J, Edelman SV, Polonsky WH. PMID: 28801475.

    View in:

    PubMed

       Mentions:

    82  

       Fields: 

       Translation:

    Humans
  52. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes Ther. 2017 Aug; 8(4):863-873. Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. PMID: 28646411; PMCID: PMC5544616.

    View in:

    PubMed

       Mentions:

    109  
  53. Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. Patient. 2017 06; 10(3):321-334. Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG, Koren A, Davidson MH. PMID: 27981439; PMCID: PMC5422451.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans
  54. Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with Diabetes. Am J Med. 2017 05; 130(5):614. Edelman SV, Hollander PA, Wright EE. PMID: 28431671.

    View in:

    PubMed   Mentions:

       Fields: 

       
  55. Physician-patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDia® study. Diabetes Res Clin Pract. 2017 May; 127:265-274. Polonsky WH, Capehorn M, Belton A, Down S, Alzaid A, Gamerman V, Nagel F, Lee J, Edelman S. PMID: 28407552.

    View in:

    PubMed

       Mentions:

    13  

       Fields: 

       Translation:

    Humans
  56. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic. J Manag Care Spec Pharm. 2017 Mar; 23(3):318-326. Hirsch JD, Bounthavong M, Arjmand A, Ha DR, Cadiz CL, Zimmerman A, Ourth H, Morreale AP, Edelman SV, Morello CM. PMID: 28230459; PMCID: PMC10398331.

    View in:

    PubMed

       Mentions:

    19  

       Fields: 

       Translation:

    Humans
  57. Administration of Biosimilar Insulin Analogs: Role of Devices. Diabetes Technol Ther. 2017 02; 19(2):79-84. Heinemann L, Fritz I, Khatami H, Edelman SV. PMID: 28118050.

    View in:

    PubMed

       Mentions:

    6  

       Fields: 

       Translation:

    Humans
  58. Investigating Hypoglycemic Confidence in Type 1 and Type 2 Diabetes. Diabetes Technol Ther. 2017 02; 19(2):131-136. Polonsky WH, Fisher L, Hessler D, Edelman SV. PMID: 27997217.

    View in:

    PubMed

       Mentions:

    53  

       Fields: 

       Translation:

    Humans
  59. Regulation Catches Up to Reality. J Diabetes Sci Technol. 2017 01; 11(1):160-164. Edelman SV. PMID: 27630249; PMCID: PMC5375077.

    View in:

    PubMed

       Mentions:

    26  

       Fields: 

       Translation:

    HumansPHPublic Health
  60. Differences in Use of Glucose Rate of Change (ROC) Arrows to Adjust Insulin Therapy Among Individuals With Type 1 and Type 2 Diabetes Who Use Continuous Glucose Monitoring (CGM). J Diabetes Sci Technol. 2016 09; 10(5):1087-93. Pettus J, Edelman SV. PMID: 27044518; PMCID: PMC5032948.

    View in:

    PubMed

       Mentions:

    12  

       Fields: 

       Translation:

    Humans
  61. Recommendations for Using Real-Time Continuous Glucose Monitoring (rtCGM) Data for Insulin Adjustments in Type 1 Diabetes. J Diabetes Sci Technol. 2017 01; 11(1):138-147. Pettus J, Edelman SV. PMID: 27530720; PMCID: PMC5375074.

    View in:

    PubMed

       Mentions:

    54  

       Fields: 

       Translation:

    Humans
  62. Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need? Adv Ther. 2016 08; 33(8):1267-78. McGill JB, Ahn D, Edelman SV, Kilpatrick CR, Santos Cavaiola T. PMID: 27384191.

    View in:

    PubMed

       Mentions:

    5  

       Fields: 

       Translation:

    Humans
  63. Improvement of Insulin Injection Technique: Examination of Current Issues and Recommendations. Diabetes Educ. 2016 08; 42(4):379-94. Spollett G, Edelman SV, Mehner P, Walter C, Penfornis A. PMID: 27216036.

    View in:

    PubMed

       Mentions:

    40  

       Fields: 

       Translation:

    Humans
  64. Unblinded CGM Should Replace Blinded CGM in the Clinical Management of Diabetes. J Diabetes Sci Technol. 2016 05; 10(3):793-8. Ahn D, Pettus J, Edelman S. PMID: 26884422; PMCID: PMC5038541.

    View in:

    PubMed

       Mentions:

    15  

       Fields: 

       Translation:

    Humans
  65. Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring. Diabetes Technol Ther. 2016 Feb; 18 Suppl 2:S234-42. Pettus J, Edelman SV. PMID: 26784128; PMCID: PMC4717500.

    View in:

    PubMed

       Mentions:

    18  

       Fields: 

       Translation:

    Humans
  66. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016 09; 32(6):478-96. Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. PMID: 26509843.

    View in:

    PubMed

       Mentions:

    35  

       Fields: 

       Translation:

    Humans
  67. Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management "Tune Up" Clinic in Complex Patients. Ann Pharmacother. 2016 Jan; 50(1):8-16. Morello CM, Christopher ML, Ortega L, Khoan J, Rotunno T, Edelman SV, Henry RR, Hirsch JD. PMID: 26546580.

    View in:

    PubMed

       Mentions:

    11  

       Fields: 

       Translation:

    Humans
  68. BIOSIMILARS AND NEW INSULIN VERSIONS. Endocr Pract. 2015 Dec; 21(12):1387-94. Peters AL, Pollom RD, Zielonka JS, Carey MA, Edelman SV. PMID: 26340139.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  69. Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes. Diabetes Technol Ther. 2015 Nov; 17(11):773-9. Polonsky WH, Fisher L, Hessler D, Edelman SV. PMID: 26167948.

    View in:

    PubMed

       Mentions:

    21  

       Fields: 

       Translation:

    Humans
  70. Development of a New Measure for Assessing Glucose Monitoring Device-Related Treatment Satisfaction and Quality of Life. Diabetes Technol Ther. 2015 Sep; 17(9):657-63. Polonsky WH, Fisher L, Hessler D, Edelman SV. PMID: 25923812.

    View in:

    PubMed

       Mentions:

    43  

       Fields: 

       Translation:

    Humans
  71. HOW PATIENTS WITH TYPE 1 DIABETES TRANSLATE CONTINUOUS GLUCOSE MONITORING DATA INTO DIABETES MANAGEMENT DECISIONS. Endocr Pract. 2015 Jun; 21(6):613-20. Pettus J, Price DA, Edelman SV. PMID: 25716635.

    View in:

    PubMed

       Mentions:

    40  

       Fields: 

       Translation:

    Humans
  72. Comment on Little et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 2014;37:2114-2122. Diabetes Care. 2014 Dec; 37(12):e270-1. Edelman SV. PMID: 25414404.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans
  73. Response to comment on Edelman et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care 2014;37:2132-2140. Diabetes Care. 2014 Dec; 37(12):e263-4. Edelman SV, Liu R, Johnson J, Glass LC. PMID: 25414399.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  74. Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetes. Am J Manag Care. 2014 Nov 01; 20(11):e490-7. David G, Gill M, Gunnarsson C, Shafiroff J, Edelman S. PMID: 25730348.

    View in:

    PubMed

       Mentions:

    4  

       Fields: 

       Translation:

    Humans
  75. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med. 2014 Oct; 127(10 Suppl):S11-6. Edelman S, Pettus J. PMID: 25282008.

    View in:

    PubMed

       Mentions:

    18  

       Fields: 

       Translation:

    Humans
  76. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015 Mar; 38(3):412-9. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, Griffen SC. PMID: 25271207.

    View in:

    PubMed

       Mentions:

    88  

       Fields: 

       Translation:

    Humans
  77. Higher proinflammatory cytokine production and spontaneous activation in some type 1 and type 2 diabetic subjects. Clin Immunol. 2014 Nov; 155(1):27-29. Sarikonda G, Sachithanantham S, Pettus J, Rodriguez-Calvo T, Phatak S, Edelman S, von Herrath M. PMID: 25173803.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    HumansCells
  78. Biosimilar insulins are coming: what they are, what you need to know. Curr Med Res Opin. 2014 Nov; 30(11):2217-22. Edelman S, Polonsky WH, Parkin CG. PMID: 25105307.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  79. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014 Aug 01; 36(8):1275-89. Santos Cavaiola T, Edelman S. PMID: 25044021.

    View in:

    PubMed

       Mentions:

    25  

       Fields: 

       Translation:

    Humans
  80. Testing versus guessing blood glucose values: impact on self-care behaviors in type 2 diabetes. Curr Med Res Opin. 2014 Sep; 30(9):1795-802. Pettus J, Stenger P, Schachner HC, Dunne N, Parkes JL, Pardo S, Edelman SV. PMID: 24889281.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    HumansCTClinical Trials
  81. Biosimilar insulins are coming: the top 10 things you should know. Postgrad Med. 2014 May; 126(3):107-10. Blumer I, Edelman S. PMID: 24918796.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  82. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care. 2014 Aug; 37(8):2132-40. Edelman SV, Liu R, Johnson J, Glass LC. PMID: 24742662.

    View in:

    PubMed

       Mentions:

    12  

       Fields: 

       Translation:

    Humans
  83. The Impact of Nocturnal Hypoglycemia on Clinical and Cost-Related Issues in Patients With Type 1 and Type 2 Diabetes. Diabetes Educ. 2014 05; 40(3):269-279. Edelman SV, Blose JS. PMID: 24695260.

    View in:

    PubMed

       Mentions:

    15  

       Fields: 

       Translation:

    Humans
  84. Impact of Biosimilar Insulins on Clinical Practice: Meeting Report. J Diabetes Sci Technol. 2014 Jan; 8(1):179-185. Dolinar RO, Edelman S, Heinemann L, Home P, Goyal S, Polonsky WH, Schellekens H. PMID: 24876554; PMCID: PMC4454104.

    View in:

    PubMed

       Mentions:

    6  

       Fields: 

       
  85. Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study. J Diabetes Sci Technol. 2014 Jan; 8(1):123-131. Stauder U, Enginee D, Elton H, Penfornis A, Edelman S. PMID: 24876548; PMCID: PMC4454110.

    View in:

    PubMed

       Mentions:

    8  

       Fields: 

       
  86. CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes. J Autoimmun. 2014 May; 50:77-82. Sarikonda G, Pettus J, Phatak S, Sachithanantham S, Miller JF, Wesley JD, Cadag E, Chae J, Ganesan L, Mallios R, Edelman S, Peters B, von Herrath M. PMID: 24387802.

    View in:

    PubMed

       Mentions:

    44  

       Fields: 

       Translation:

    HumansCells
  87. Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessment. PLoS One. 2013; 8(11):e79383. Sarikonda G, Pettus J, Sachithanantham S, Phatak S, Miller JF, Ganesan L, Chae J, Mallios R, Edelman S, Peters B, von Herrath M. PMID: 24223938; PMCID: PMC3817042.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    HumansCells
  88. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am. 2013 Dec; 42(4):809-32. Boland BS, Edelman SV, Wolosin JD. PMID: 24286951; PMCID: PMC6658178.

    View in:

    PubMed

       Mentions:

    11  

       Fields: 

       Translation:

    Humans
  89. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med. 2013 May; 125(3):136-44. Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, Maggs D, Kolterman OG. PMID: 23748514.

    View in:

    PubMed

       Mentions:

    12  

       Fields: 

       Translation:

    Humans
  90. GLP-1 agonists in type 1 diabetes. Clin Immunol. 2013 Dec; 149(3):317-23. Pettus J, Hirsch I, Edelman S. PMID: 23643354.

    View in:

    PubMed

       Mentions:

    15  

       Fields: 

       Translation:

    HumansAnimalsCells
  91. Effect of early weight loss on type 2 diabetes mellitus after 2 years of gastric banding. Postgrad Med. 2012 Nov; 124(6):73-81. Edelman S, Bhoyrul S, Billy H, Cornell C, Okerson T. PMID: 23322140.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    HumansCTClinical Trials
  92. Using multiple measures of glycemia to support individualized diabetes management: recommendations for clinicians, patients, and payers. Diabetes Technol Ther. 2012 Nov; 14(11):973-83; quiz 983. Hirsch IB, Amiel SA, Blumer IR, Bode BW, Edelman SV, Seley JJ, Verderese CA, Kilpatrick ES. PMID: 23066850.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans
  93. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med. 2012 07 26; 367(4):383; author reply 383-4. Blumer I, Edelman SV, Hirsch IB. PMID: 22830479.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  94. A survey of blood glucose monitoring in patients with type 2 diabetes: are recommendations from health care professionals being followed? Curr Med Res Opin. 2011 Nov; 27 Suppl 3:31-7. Polonsky WH, Fisher L, Hessler D, Edelman SV. PMID: 22106976.

    View in:

    PubMed

       Mentions:

    24  

       Fields: 

       Translation:

    HumansCTClinical Trials
  95. A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections. J Diabetes Sci Technol. 2011 Jul 01; 5(4):887-93. Frias JP, Bode BW, Bailey TS, Kipnes MS, Brunelle R, Edelman SV. PMID: 21880230; PMCID: PMC3192594.

    View in:

    PubMed

       Mentions:

    12  

       Fields: 

       Translation:

    HumansCTClinical Trials
  96. Ethnic differences in complementary and alternative medicine use among patients with diabetes. Complement Ther Med. 2010 Dec; 18(6):241-8. Villa-Caballero L, Morello CM, Chynoweth ME, Prieto-Rosinol A, Polonsky WH, Palinkas LA, Edelman SV. PMID: 21130360; PMCID: PMC3003303.

    View in:

    PubMed

       Mentions:

    19  

       Fields: 

       Translation:

    HumansAnimals
  97. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid. 2010 Oct 21; 5:23-37. Kulasa K, Edelman S. PMID: 21042540; PMCID: PMC2963920.

    View in:

    PubMed

       Mentions:

    9  
  98. Are patients' initial experiences at the diagnosis of type 2 diabetes associated with attitudes and self-management over time? Diabetes Educ. 2010 Sep-Oct; 36(5):828-34. Polonsky WH, Fisher L, Guzman S, Sieber WJ, Philis-Tsimikas A, Edelman SV. PMID: 20729511.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  99. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther. 2010 Aug; 12(8):627-33. Edelman SV, Bode BW, Bailey TS, Kipnes MS, Brunelle R, Chen X, Frias JP. PMID: 20615104.

    View in:

    PubMed

       Mentions:

    23  

       Fields: 

       Translation:

    HumansCTClinical Trials
  100. Insulin pen use for type 2 diabetes--a clinical perspective. Diabetes Technol Ther. 2010 Jun; 12 Suppl 1:S86-90. Bailey TS, Edelman SV. PMID: 20515313.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  101. Continuous glucose monitoring health outcomes. Diabetes Technol Ther. 2009 Jun; 11 Suppl 1:S68-74. Edelman SV, Bailey TS. PMID: 19469680.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans
  102. United States patient preference and usability for the new disposable insulin device Solostar versus other disposable pens. J Diabetes Sci Technol. 2008 Nov; 2(6):1157-60. Fischer JS, Edelman SV, Schwartz SL. PMID: 19885306; PMCID: PMC2769811.

    View in:

    PubMed

       Mentions:

    10  

       Fields: 

       
  103. Does addition of pramlintide to basal insulin improve glycemic control in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):194-5. Edelman SV. PMID: 18283327.

    View in:

    PubMed   Mentions:

       Fields: 

       
  104. Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008; 22(6):375-86. Edelman S, Maier H, Wilhelm K. PMID: 18998755.

    View in:

    PubMed

       Mentions:

    24  

       Fields: 

       Translation:

    Humans
  105. Optimizing diabetes treatment using an amylin analogue. Diabetes Educ. 2008 Jan-Feb; 34 Suppl 1:4S-10S. Edelman SV. PMID: 18268000.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       
  106. The role of self-monitoring of blood glucose during the treatment of type 2 diabetes with medications targeting postprandial hyperglycemia. South Med J. 2007 Nov; 100(11):1123-31. Choe C, Edelman SV. PMID: 17984745.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans
  107. Incretins and their role in the management of diabetes. Curr Opin Endocrinol Diabetes Obes. 2007 Aug; 14(4):269-76. Frias JP, Edelman SV. PMID: 17940451.

    View in:

    PubMed

       Mentions:

    6  

       Fields: 

       Translation:

    HumansCells
  108. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab. 2007 May; 3(5):E1; discussion E2. Edelman SV, Garg S, Kolterman OG. PMID: 17452962.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  109. A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. Osteopath Med Prim Care. 2007 Apr 20; 1:9. Edelman S, Dailey G, Flood T, Kuritzky L, Renda S. PMID: 17448241; PMCID: PMC1885266.

    View in:

    PubMed

       Mentions:

    11  
  110. New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs. J Natl Med Assoc. 2007 Apr; 99(4):357-60, 363-7. Choe C, Edelman S. PMID: 17444424; PMCID: PMC2569656.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  111. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007 Apr; 29(4):650-60. Haak T, Edelman S, Walter C, Lecointre B, Spollett G. PMID: 17617288.

    View in:

    PubMed

       Mentions:

    23  

       Fields: 

       Translation:

    Humans
  112. Significant insulin dose errors may occur if blood glucose results are obtained from miscoded meters. J Diabetes Sci Technol. 2007 Mar; 1(2):205-10. Raine CH, Schrock LE, Edelman SV, Mudaliar SR, Zhong W, Proud LJ, Parkes JL. PMID: 19888408; PMCID: PMC2771463.

    View in:

    PubMed

       Mentions:

    20  

       Fields: 

       
  113. Through the looking glass: current and future perspectives on the role of hormonal interplay in glucose homeostasis. Diabetes Educ. 2007 02; 33 Suppl 2:32S-46S; quiz 47S-48S. Kruger DF, Aronoff SL, Edelman SV. PMID: 17483531.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans
  114. Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus. Expert Rev Endocrinol Metab. 2007 Jan; 2(1):9-18. Edelman SV, Schroeder BE, Frias JP. PMID: 30743744.

    View in:

    PubMed   Mentions:

       Fields: 

       
  115. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct; 29(10):2189-95. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. PMID: 17003291.

    View in:

    PubMed

       Mentions:

    46  

       Fields: 

       Translation:

    Humans
  116. Amylin replacement therapy in patients with type 1 diabetes. Diabetes Educ. 2006 May-Jun; 32 Suppl 3:119S-127S. Edelman SV, Caballero L. PMID: 16751353.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       Translation:

    Humans
  117. Does a patient-administered titration algorithm of insulin glargine improve glycemic control? Nat Clin Pract Endocrinol Metab. 2006 Feb; 2(2):78-9. Edelman S. PMID: 16932261.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  118. Incretins: what does the future hold? Diabetes Technol Ther. 2005 Oct; 7(5):809-12. Edelman SV. PMID: 16241889.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans
  119. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005 Oct; 28(10):2543-5. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. PMID: 16186296.

    View in:

    PubMed

       Mentions:

    187  

       Fields: 

       Translation:

    Humans
  120. Strategies for insulin therapy in type 2 diabetes. South Med J. 2005 Mar; 98(3):363-71. Edelman SV, Morello CM. PMID: 15813164.

    View in:

    PubMed

       Mentions:

    5  

       Fields: 

       Translation:

    Humans
  121. Thiazolidinediones. N Engl J Med. 2005 Jan 13; 352(2):205-7; author reply 205-7. Edelman SV. PMID: 15651124.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  122. Hypoglycemia unawareness and type 1 diabetes. South Med J. 2004 Nov; 97(11):1143-4. Edelman SV, Morello CM. PMID: 15586620.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  123. Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab. 2005 Jan; 90(1):352-8. Ciaraldi TP, Mudaliar S, Barzin A, Macievic JA, Edelman SV, Park KS, Henry RR. PMID: 15483099.

    View in:

    PubMed

       Mentions:

    21  

       Fields: 

       Translation:

    Humans
  124. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2004 Sep 01; 44(5):1047-52. Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, Krishnaswamy P, Morrison LK, Chiu A, Gardetto N, Mudaliar S, Edelman SV, Henry RR, Maisel AS. PMID: 15337217.

    View in:

    PubMed

       Mentions:

    25  

       Fields: 

       Translation:

    Humans
  125. Insulin therapy in type 2 diabetes. Med Clin North Am. 2004 Jul; 88(4):865-95, x. Davis T, Edelman SV. PMID: 15308383.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       Translation:

    Humans
  126. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004 Mar; 27(3):734-8. Garg SK, Schwartz S, Edelman SV. PMID: 14988294.

    View in:

    PubMed

       Mentions:

    39  

       Fields: 

       Translation:

    Humans
  127. BNP levels to screen for left ventricular dysfunction. Curr Diab Rep. 2004 Feb; 4(1):39-40. Chu NV, Edelman SV. PMID: 14764278.

    View in:

    PubMed   Mentions:

       Fields: 

       
  128. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care. 2003 Jul; 26(7):2081-7. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, Edelman S, Henry R, Maisel A. PMID: 12832317.

    View in:

    PubMed

       Mentions:

    29  

       Fields: 

       Translation:

    Humans
  129. Osteoporosis and diabetes. Curr Diab Rep. 2003 Feb; 3(1):37-42. Chau DL, Edelman SV, Chandran M. PMID: 12643144.

    View in:

    PubMed

       Mentions:

    27  

       Fields: 

       Translation:

    Humans
  130. Pramlintide as an adjunct to insulin therapy. Curr Diab Rep. 2003 Feb; 3(1):35-6. Chu NV, Edelman SV. PMID: 12685439.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       
  131. Gastrointestinal disturbances in diabetes. Curr Diab Rep. 2003 Feb; 3(1):43-8. Chandran M, Chu NV, Edelman SV. PMID: 12643145.

    View in:

    PubMed

       Mentions:

    9  

       Fields: 

       Translation:

    Humans
  132. Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol Ther. 2003; 5(3):355-63. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. PMID: 12828817.

    View in:

    PubMed

       Mentions:

    87  

       Fields: 

       Translation:

    HumansCellsPHPublic Health
  133. Aiming for, believing in, and achieving a target A1c of less than 7. J Am Pharm Assoc (Wash). 2003 Jan-Feb; 43(1):121-2. Edelman S. PMID: 12585763.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans
  134. Aiming for, believing in, and achieving a target a1c of less than 7. J Am Pharm Assoc (Wash). 2003 Jan; 43(1):121-2. Edelman S. PMID: 23945818.

    View in:

    PubMed   Mentions:

       Fields: 

       
  135. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. Rev Cardiovasc Med. 2003; 4 Suppl 6:S29-37. Edelman SV. PMID: 14668701.

    View in:

    PubMed

       Mentions:

    4  

       Fields: 

       Translation:

    Humans
  136. Pumps and type 2 diabetes. If you can improve your diabetes control, and if you can accommodate yourself to it, the pump might just be the best diabetes therapy for you. Diabetes Forecast. 2002 Jun; 55(6):62-5. Edelman SV. PMID: 14964172.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans
  137. Insulin pump therapy versus multiple daily injections. Curr Diab Rep. 2002 Feb; 2(1):47-8. Edelman SV. PMID: 15279019.

    View in:

    PubMed   Mentions:

       Fields: 

       
  138. Erectile dysfunction and diabetes. Curr Diab Rep. 2002 Feb; 2(1):60-6. Chu NV, Edelman SV. PMID: 12643124.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans
  139. Pharmacokinetics and glucodynamics of rapid-, short-, and intermediate-acting insulins: comparison of jet injection to needle syringe. Diabetes Technol Ther. 2002; 4(6):863-6. Sarno MJ, Bell J, Edelman SV. PMID: 12614490.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       Translation:

    Humans
  140. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther. 2002; 4(2):175-89. Edelman SV, Weyer C. PMID: 12079621.

    View in:

    PubMed

       Mentions:

    22  

       Fields: 

       Translation:

    HumansAnimalsCells